HER3, serious partner in crime: therapeutic approaches and potential biomarkers for effect of HER3-targeting.
作者： Arjan Kol , Anton G.T. Terwisscha van Scheltinga , Hetty Timmer-Bosscha , Laetitia E. Lamberts , Frederike Bensch
DOI: 10.1016/J.PHARMTHERA.2014.01.005
关键词:
摘要: The human epidermal growth factor receptor (HER) family members are targeted by a growing numbers of small molecules and monoclonal antibodies. Resistance against the (EGFR) HER2-targeting agents is clinically relevant problem forcing research on optimizing targeting HER family. In view its overexpression in tumors, compensatory role signaling, HER3 has gained much interest as potential additional target within It only member lacking intrinsic tyrosine kinase activity therefore cancer long been underestimated. Drugs that block or interfere with dimer including fully anti-HER3 antibodies, bispecific antibodies inhibitors (TKIs), currently becoming available. Several compounds have already entered clinical trial. meantime biomarkers tested such tumor analysis expression, functional assays for downstream effector molecular imaging techniques. This review describes biology relevance cancer, effect HER3-targeting.
narcis.nl
elsevier.com参考文章(120)
Edward Htun van der Horst, Igor Weber, Axel Ullrich, Tyrosine phosphorylation of PYK2 mediates heregulin-induced glioma invasion: novel heregulin/HER3-stimulated signaling pathway in glioma. International Journal of Cancer. ,vol. 113, pp. 689- 698 ,(2005) , 10.1002/IJC.20643
Charlotte F. McDonagh, Alexandra Huhalov, Brian D. Harms, Sharlene Adams, Violette Paragas, Shinji Oyama, Bo Zhang, Lia Luus, Ryan Overland, Stephanie Nguyen, Jinming Gu, Neeraj Kohli, Matt Wallace, Michael J. Feldhaus, Arthur J. Kudla, Birgit Schoeberl, Ulrik B. Nielsen, Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3 Molecular Cancer Therapeutics. ,vol. 11, pp. 582- 593 ,(2012) , 10.1158/1535-7163.MCT-11-0820
L Gianni, G Bianchini, A Kiermaier, G Bianchi, Y-H Im, T Pienkowski, L Roman, M-C Liu, L-M Tseng, J Ratnayake, T Szado, GA Ross, P Valagussa, S5-1: Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Biomarker Analyses of a 4-Arm Randomized Phase II Study (NeoSphere) in Patients (pts) with HER2−Positive Breast Cancer (BC). Cancer Research. ,vol. 71, ,(2011) , 10.1158/0008-5472.SABCS11-S5-1
Stephen Johnston, Maureen Trudeau, Bella Kaufman, Hamouda Boussen, Kimberley Blackwell, Patricia LoRusso, Donald P. Lombardi, Slim Ben Ahmed, Dennis L. Citrin, Michelle L. DeSilvio, Jennifer Harris, Ron E. Westlund, Vanessa Salazar, Tal Z. Zaks, Neil L. Spector, Phase II Study of Predictive Biomarker Profiles for Response Targeting Human Epidermal Growth Factor Receptor 2 (HER-2) in Advanced Inflammatory Breast Cancer With Lapatinib Monotherapy Journal of Clinical Oncology. ,vol. 26, pp. 1066- 1072 ,(2008) , 10.1200/JCO.2007.13.9949
Maria D. Begnami, Emy Fukuda, José H.T.G. Fregnani, Suely Nonogaki, André L. Montagnini, Wilson L. da Costa, Fernando A. Soares, Prognostic Implications of Altered Human Epidermal Growth Factor Receptors (HERs) in Gastric Carcinomas: HER2 and HER3 Are Predictors of Poor Outcome Journal of Clinical Oncology. ,vol. 29, pp. 3030- 3036 ,(2011) , 10.1200/JCO.2010.33.6313
Sarat Chandarlapaty, Ayana Sawai, Maurizio Scaltriti, Vanessa Rodrik-Outmezguine, Olivera Grbovic-Huezo, Violeta Serra, Pradip K. Majumder, Jose Baselga, Neal Rosen, AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity Cancer Cell. ,vol. 19, pp. 58- 71 ,(2011) , 10.1016/J.CCR.2010.10.031
Shyhmin Huang, Chunrong Li, Eric A. Armstrong, Chimera R. Peet, Jarob Saker, Lukas C. Amler, Mark X. Sliwkowski, Paul M. Harari, Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation Cancer Research. ,vol. 73, pp. 824- 833 ,(2013) , 10.1158/0008-5472.CAN-12-1611
Xiaoping Huang, Lizhi Gao, Shuiliang Wang, Choon-Kee Lee, Peter Ordentlich, Bolin Liu, HDAC Inhibitor SNDX-275 Induces Apoptosis in erbB2-Overexpressing Breast Cancer Cells via Down-regulation of erbB3 Expression Cancer Research. ,vol. 69, pp. 8403- 8411 ,(2009) , 10.1158/0008-5472.CAN-09-2146
Mikiko Hayashi, Mikito Inokuchi, Yoko Takagi, Hiroyuki Yamada, Kazuyuki Kojima, Jiro Kumagai, Tatsuyuki Kawano, Kenichi Sugihara, High Expression of HER3 Is Associated with a Decreased Survival in Gastric Cancer Clinical Cancer Research. ,vol. 14, pp. 7843- 7849 ,(2008) , 10.1158/1078-0432.CCR-08-1064
Patrick J. Perik, Marjolijn N. Lub-De Hooge, Jourik A. Gietema, Winette T.A. van der Graaf, M. Alexander de Korte, Sharon Jonkman, Jos G.W. Kosterink, Dirk J. van Veldhuisen, Dirk T. Sleijfer, Pieter L. Jager, Elisabeth G.E. de Vries, Indium-111–Labeled Trastuzumab Scintigraphy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Journal of Clinical Oncology. ,vol. 24, pp. 2276- 2282 ,(2006) , 10.1200/JCO.2005.03.8448